<DOC>
	<DOCNO>NCT01458119</DOCNO>
	<brief_summary>This long term , open label study migalastat HCl ( AT1001 ) subject Fabry disease complete treatment previous monotherapy trial migalastat hydrochloride ( HCl ) .</brief_summary>
	<brief_title>Open-Label Phase 3 Long-Term Safety Study Migalastat</brief_title>
	<detailed_description>AT1001-041 open-label , non-comparative , multicenter , long term extension study subject Fabry disease complete treatment previous trial migalastat HCl ( also know AT1001 ) give monotherapy . This extension study design evaluate long-term safety efficacy migalastat HCl treatment Fabry disease . Study visit occur every 6 month evaluate safety ass efficacy . Visit evaluation include physical examination , clinical laboratory parameter , adverse event patient report outcome .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Completed migalastat HCl treatment previous Fabry disease protocol Both : female male participant study Ages 16 year old Males female must agree use protocol identify acceptable contraception Estimated glomerular filtration rate previous study &lt; 30 mL/min/1.73m2 ; unless measure GFR available within 3 month Baseline Visit ( Visit 1 ) , &gt; 30 mL/min/1.73m2 Has undergone , schedule undergo kidney transplantation currently dialysis Pregnancy breast feeding Treated another investigational drug ( except migalastat HCl ) within 30 day study start Unable comply study requirement , deem otherwise unsuitable study entry , opinion investigator Has document transient ischemic attack , stroke , unstable angina , myocardial infarction within 12 month Visit 1 Has clinically significant unstable cardiac disease opinion investigator Has history allergy sensitivity AT1001 ( include excipients ) iminosugars Requires treatment Glyset , ( miglitol ) , Zavesca ( miglustat ) Has intercurrent illness condition may preclude subject fulfil protocol requirement Patients severe unsuitable concomitant medical condition Patients clinically significant abnormal laboratory value ( ) clinically significant electrocardiogram ( ECG ) finding baseline .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>Lysosomal storage disease</keyword>
	<keyword>migalastat HCl</keyword>
	<keyword>AT1001</keyword>
</DOC>